Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) signs a licence and distribution agreement with Isologic Innovative Pharmaceuticals for its investigational prostate cancer imaging agent Illuccix
- Under the agreement, Isologic will be the commercial distributor of Illuccix in Canada for four years, subject to achieving annual minimum sales
- Isologic’s President Dr André Gagnon said PSMA PET imaging is a new technology that could transform the way prostate cancer is initially staged and managed
- According to the Canadian Cancer Society, prostate cancer is the most common cause of cancer
- TLX are up 1.96 per cent and trading at $4.17 per share at market close
Telix Pharmaceuticals (TLX) has signed a licence and distribution agreement with Isologic Innovative Pharmaceuticals for its investigational prostate cancer imaging agent Illuccix.
Isologic is the leading radiopharmaceutical network in Canada, servicing 265 hospitals and clinics across the country.
Under the agreement, Isologic will be the commercial distributor of Illuccix in Canada for four years, subject to achieving annual minimum sales.
Isologic’s President Dr André Gagnon said PSMA PET imaging is a new technology that could transform the way prostate cancer is initially staged and managed.
“We are very pleased to be working with Telix to bring this diagnostic imaging agent to our customers and patients in Canada, following regulatory approval by Health Canada,” he said.
Telix CEO and Managing Director Dr Christian Behrenbruch said Canada is an important
market for the company.
“Therefore, we are pleased to have secured this agreement, which will help patients across Canada access PSMA PET imaging using Illuccix once we have regulatory approval,” he added.
According to the Canadian Cancer Society, prostate cancer is the most common cause of cancer after non-melanoma skin cancers and is the third-leading cause of death from cancer amongst Canadian men.
On the market, TLX was up 1.96 per cent and trading at $4.17 per share at market phone.
